AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01247454 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Electronic Health Record (EHR) prompt
Description: EHR message that encourages providers to consider ASA therapy for patients at high-risk for developing cardiovascular disease is replaced with a message asking providers to consider terminating aspirin in patients who do not have appropriate cardiovascular disease.
Study NCT01247454 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: EHR prompt and patient prompt
Description: EHR message that encourages providers to consider ASA therapy for patients at high-risk for developing cardiovascular disease is replaced with a message asking providers to consider terminating aspirin in patients who do not have appropriate cardiovascular disease. And a brief information sheet is distributed to patients prior to their visit asking them to discuss ASA therapy for primary prevention with their provider.
Study NCT03036852 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SOF/VEL
Description: 400/100 mg fixed-dose combination (FDC) tablet(s) administered orally once daily
Study NCT01820806 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 100 mg dose of [14C] GLPG0634
Description: Subjects will be dosed with a single oral 100 mg dose of \[14C\] GLPG0634 on one occasion
Study NCT02611102 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: MCT oil + Butter in Coffee
Description: 2 tablespoons medium-chain triglyceride oil + 2 tablespoons butter added to 2-4 cups of coffee similar to their usual intake prior to 1200 daily over a 4 week period after a 2 week run-in phase during which the doses of butter and MCT oil will be titrated up (1 Tbsp. of each butter + MCT x 5 days, 2 Tbsp. butter + 1 Tbsp. MCT x 5 days, then 2 Tbsp. of each x 4 days) followed by 6 weeks of washout without treatment.
Study NCT02611102 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: MCT oil + Butter in Coffee
Description: 2 tablespoons medium-chain triglyceride oil + 2 tablespoons butter added to 2-4 cups of coffee similar to their usual intake prior to 1200 daily over a 4 week period after a 2 week run-in phase during which the doses of butter and MCT oil will be titrated up (1 Tbsp. of each butter + MCT x 5 days, 2 Tbsp. butter + 1 Tbsp. MCT x 5 days, then 2 Tbsp. of each x 4 days) followed by 6 weeks of washout without treatment.
Study NCT00977483 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thioctic Acid
Description: 600mg tablet once daily 4 years double-blind treatment period
Study NCT00977483 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 tablet once daily 4 years double-blind treatment period
Study NCT01739894 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IP Paclitaxel
Description: Each treatment cycle will consist of 21 days, with 14 days on treatment and 7 days off-treatment. Oxaliplatin will be administered intravenously (on Day 1 of each cycle). Paclitaxel will be administered intra-abdominally on Day 1 and Day 8 of each cycle. In particular, a needle will be inserted into the intraperitoneal injection port for normal saline to be injected intra-abdominally over one hour, followed by paclitaxel chemotherapy over a further one hour. Capecitabine will be taken by mouth from Day 1 to 14 of each cycle.
Study NCT02563730 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lung biopsy
Description: transbronchial lung biopsy. First kryobiopsy, second open biopsy
Study NCT06030219 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omadacycline
Description: 10-day course
Study NCT06030219 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vancomycin Pill
Description: 10-day course
Study NCT06030219 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Moxifloxacin
Description: 10-day course
Study NCT03130218 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Peppermint oil aromatherapy
Description: Aroma therapy with peppermint oil administered with presoaked diffuser and bag.
Study NCT05610592 — intervention group
Intervention type: PROCEDURE
Intervention: total mesorectal exicision
Study NCT02387983 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Posaconazole
Description: Posaconazole 300 mg solid oral tablet
Study NCT01527136 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: entolimod
Description: Given IM or SC
Study NCT01527136 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies
Study NCT01527136 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT04402775 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tourniquet
Description: A tourniquet will be used during surgery
Study NCT00877604 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tauroursodeoxycholic acid (TUDCA)
Description: Oral route at the dose of 1 g b.i.d. (2 g daily) for 1 year
Study NCT03214874 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Demadex 20mg Tablet
Description: Immediate Release (IR) Torsemide
Study NCT03214874 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ER Torsemide 20mg Tablet
Description: Extended Release Torsemide 20 mg tablet given once daily
Study NCT02583893 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus
Description: Given PO
Study NCT02583893 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitoxantrone
Description: Given IV
Study NCT02583893 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Given IV
Study NCT02583893 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Given IV
Study NCT02833545 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ozone gas
Description: Injection of ozone gas intra articularly
Study NCT02833545 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Steroid injection
Description: Injection of steroids (diprospan) intra articularly
Study NCT02426853 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Questionnaires
Description: Participants complete 1 questionnaire at beginning of study, 1 after receiving education about how to protect skin from sun and how to avoid tanning beds, and 1 at about 3 months after receiving skin protection education.
Study NCT02426853 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaires
Description: Participants complete 1 questionnaire at beginning of study, 1 after receiving education about how to protect skin from sun and how to avoid tanning beds, and 1 at about 3 months after receiving skin protection education.
Study NCT02426853 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Photos
Description: At beginning of study, 2 photos taken of the face. One photo is a standard photo, the other photo is taken with an ultraviolet (UV) filter.
Study NCT02426853 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pamphlets
Description: At beginning of study, handouts given that discusses skin cancer prevention, sun protection, and how to avoid tanning beds.
Study NCT02426853 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Pamphlets
Description: At beginning of study, handouts given that discusses skin cancer prevention, sun protection, and how to avoid tanning beds.
Study NCT02293330 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: continuous infusion of levobupivacaine
Description: continuous infusion of levobupivacaine 0,125% at 5 ml/h , bolus dose 6 ml, lock out 30 minutes 4 hours limit: 60 ml/h
Study NCT02293330 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intermittent bolus infusion of levobupivacaine
Description: Intermittent bolus of levobupivacaine 0,125%: 0.1 ml /h and 9,8 ml bolus every two hours. Optional patient controlled bolus dose 6 ml, lock out 30 minutes, 4 hours limit: 60 ml/h
Study NCT00821873 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CR Plug
Description: CR Plug will be placed in the harvest site
Study NCT04008966 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: combined oral contaraceptive pills
Description: 1 tablet daily between days 5 and 25 of the cycle before stimulation
Study NCT04008966 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: recombinant FSH
Description: 300 U from the 2nd day of the cycle then the dose was adjusted according to the ovarian response evaluated by transvaginal ultrasound and serum E2
Study NCT00877604 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: identical placebo by oral route at the same dosing schedule
Study NCT04008966 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Urinaru gonadotropin
Description: 150 U from the 2nd day of the cycle then the dose was adjusted according to the ovarian response evaluated by transvaginal ultrasound and serum E2
Study NCT04008966 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GnRH antagonist
Description: 0.25 subcutaneously daily from the day in which the leading follicles reached 12 mm till the day of triggering
Study NCT04008966 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Human chorionic gonadotropin
Description: 10,000 IU intramuscular when at least 3 follicles larger than 14 mm and at least one of them reached a mean diameter of 17 mm or more
Study NCT04008966 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GnRH agonist
Description: 0.2 mg subcutaneously when at least 3 follicles larger than 14 mm and at least one of them reached a mean diameter of 17 mm or more
Study NCT04008966 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ovum pick up
Description: 34 hours after triggering under the guidance of transvaginal ultrasound
Study NCT04008966 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Embryo transfer
Description: Transabdominal ultrasound guided embryo transfer was done 3 days after oocyte retrieval using Labotect semirigid catheter
Study NCT04008966 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: natural Progesterone
Description: 400 mg twice daily per vagina
Study NCT02074592 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self assessment of ultrasound fetal biometry images
Description: self assessment of ultrasound fetal biometry images followed by automatically generated feedback
Study NCT02074592 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: assessment of ultrasound fetal biometry images by expert
Description: assessment of ultrasound fetal biometry images by expert, followed by automatically generated feedback
Study NCT02533375 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adalimumab
Description: Adalimumab pre-filled syringe, administered by subcutaneous injection
Study NCT00076804 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Directly Observed Therapy
Description: Use of a patient nominated peer supporter who will observe the morning dose of ARVs
Study NCT03150849 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: C-X-C Chemokine Receptor 4
Description: marker assessed by flowcytometry in a blood sample
Study NCT03039660 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: RefreshMD
Description: Online Sleep Improvement Course
Study NCT03039660 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Bond Between Us
Description: Online Educational Course
Study NCT03842579 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resistance training
Description: Supervised progressive explosive type heavy-resistance training two times per week
Study NCT03842579 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High-protein diet
Description: Daily supplementation with milk-based protein-rich products
Study NCT03842579 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: High-protein diet
Description: Daily supplementation with milk-based protein-rich products
Study NCT03842579 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Recommendations
Description: Provided with the official national recommendations on nutrition
Study NCT04161846 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual Training
Description: The intervention involves a CHW training focused on raising awareness of diabetes prevention in the community. It is delivered remotely over 10 weeks using an internet based approach.
Study NCT04161846 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: In Person Training
Description: The intervention involves a CHW training focused on raising awareness of diabetes prevention in the community. It is delivered in person over 10 weeks.
Study NCT03323853 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Computerized Assessment and Referral System (CARS) Self-Assessment Screener
Description: Subjects will take the CARS-SA Screener.
Study NCT03323853 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Computerized Assessment and Referral System (CARS) Self-Assessment Screener
Description: Subjects will take the CARS-SA Screener.
Study NCT01713049 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: 18F-FLT
Description: 0.07 mCi/kg of 18F-FDG will be injected intravenously. The data acquisition will be started at 90 minutes after the injection using 2-D acquisition from a GE DISCOVERY ST PET/CT scanner (GE Medical Systems, Milwaukee, WI).
Study NCT02563587 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laughter therapy
Description: Laughter therapy sessions will begin as soon as / after that the complete anesthesia recovery, then we could start with two interventions, each of them in morning and during the afternoon will be held until their discharge lasting 30 minutes per each one, these sessions will be held in the service pediatric hospital by trained personnel in laughter therapy, which will be implemented through hospital clowns.
Study NCT02563587 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Accompaniment without causing the laughter of children.
Description: The interventions will be carried out by means of reading stories and own stories for the age. These sessions will begin subsequent to the full recovery of the anesthesia, and then two interventions per day, in the morning and evening, with duration of 30 minutes, until the time of his discharge, these sessions will take place in the service of Hospital pediatrics by the resident in charge.
Study NCT02563587 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Conventional treatment
Description: Conventional treatment involves handling analgesic with non-steroidal anti-inflammatory drugs (paracetaol, metamizol and ketorolac) as prescribed by the doctor surgeon treating, which starts immediately in the postoperative period.
Study NCT02035904 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levobupivacaine PCIA (Patient Controlled Intrawound Analgesia)
Description: patient controlled infusion from the 2nd day after surgery
Study NCT02716935 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fortified lipid based nutrient supplement
Description: 6 months intervention: participant will take a daily dose of 20g supplement. The product contains 3 g of a mixture (1:1) of inulin and fructan-oligosaccharide
Study NCT02716935 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: lipid based nutrient supplement
Description: Dietary Supplement: lipid based nutrient supplement (Nutributter) 6 months intervention: participant will take a daily dose of 20g supplement.
Study NCT02953951 — intervention group
Intervention type: OTHER
Intervention: blood transfusion
Description: blood transfusion different sources
Study NCT00423683 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Arixtra alone
Description: Arixtra subq injection 5mg dose (dose also dependent upon size and age of pt)
Study NCT00423683 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Arixtra + filter
Description: Arixtra as daily injections similar to arm I and placement of Inferior Vena Cava (IVC) filter.
Study NCT01517230 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Local radio campaign to reduce under-five child mortality
Description: The media campaign is designed by Development Media International. It includes short spots and long format programs broadcast by rural community radios. Major topics to be addressed include: diarrhoea, water and sanitation, acute respiratory infections, fever/malaria, antenatal consultations, delivery in health facilities, breastfeeding, and child nutrition. The intervention is planned to start in March 2012 after completion of fieldwork for the baseline survey and will continue for 2.5 years.
Study NCT01340105 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Microwave ablation
Description: Use of microwave energy to ablate hepatocellular carcinoma. It can be employed by percutaneous, open surgery or laparoscopic means.
Study NCT01340105 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Radiofrequency ablation
Description: Use of radiofrequency energy to ablate hepatocellular carcinoma. It can be employed by percutaneous, open surgery or laparoscopic means.
Study NCT01097941 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Live Attenuated H1N1 Influenza Vaccine
Description: 0.2 ml dose of live monovalent vaccine delivered through nasal spray, 2 doses given 28 days apart
Study NCT01097941 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Influenza A (H1N1) 2009 Monovalent Vaccine
Description: 0.5 ml IM, 2 doses given 28 days apart
Study NCT01097941 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Influenza A (H1N1) 2009 Monovalent Vaccine/ Influenza A (H1N1) Monovalent Vaccine Live
Description: 0.5 ml IM given X1 with 0.1 ml intranasally given 28 days later
Study NCT01391741 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Visual Cues
Description: Walking with visual cues for 30 minutes, 4 times a week for 4 weeks
Study NCT01391741 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Walking without visual cues
Description: Walking without visual cues, but verbal encouragement twice a week to take longer steps, for 30 minutes, 4
Study NCT00540293 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Description: Prescription of 10/20/40mg dose atorvastatin based on the personal risk factor that is defined in the NCEP ATP III guideline in a single patient group
Study NCT02185651 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zavesca® Prescription
Description: Following baseline evaluation, Zavesca® prescription is given.~Week 2, 4, and 6 ERT infusion with pre-medication are completed at local/home infusion center. Travel to site for week 7 study visit includes physical exam, blood collection and punch muscle biopsy. Health survey is completed.
Study NCT00521027 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Versajet Hydrosurgery System
Description: Debridement with Versajet Hydrosurgery System
Study NCT02035904 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: saline
Description: patient controlled infusion from the 2nd day after surgery
Study NCT02035904 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levobupivacaine continuous infusion
Description: Continuous infusion Levobupivacaine 0,25% 5ml/h for 24 hs in all patients
Study NCT02035904 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Levobupivacaine continuous infusion
Description: Continuous infusion Levobupivacaine 0,25% 5ml/h for 24 hs in all patients
Study NCT02035904 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: intrawound infusion catheter
Description: placed by surgeon at the end surgery in all patients
Study NCT02035904 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: intrawound infusion catheter
Description: placed by surgeon at the end surgery in all patients
Study NCT02035904 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: morphine
Description: PCA with morphine: 0,5 mg/ml bolus 1 mg lock-out 5 min max 20 mg in 4 hs - for the first 24 hs as rescue analgesia
Study NCT02035904 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: morphine
Description: PCA with morphine: 0,5 mg/ml bolus 1 mg lock-out 5 min max 20 mg in 4 hs - for the first 24 hs as rescue analgesia
Study NCT03323853 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CARS-SA Summary Results
Description: Subjects will be evaluated by emergency care providers using the CARS-SA Summary Results Report.
Study NCT04199585 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lu AF95245
Description: solution, single dose, orally
Study NCT04199585 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lu AF95245 14C radiolabelled spiked dosage
Description: solution, single dose, orally
Study NCT04199585 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: solution, single dose, orally
Study NCT01087593 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 17β-estradiol
Description: Transdermal administration(50 ug daily)for a period of ten weeks with additional treatment of medroxyprogesterone (10mg daily) for the last two weeks
Study NCT01087593 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 17β-estradiol
Description: Transdermal administration(50 ug daily)for a period of ten weeks with additional treatment of medroxyprogesterone (10mg daily) for the last two weeks